Positive News SentimentPositive NewsNASDAQ:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis $1.14 -0.06 (-5.00%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$1.05 -0.09 (-8.16%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Cardiol Therapeutics Stock (NASDAQ:CRDL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cardiol Therapeutics alerts:Sign Up Key Stats Today's Range$1.13▼$1.2050-Day Range$1.14▼$2.2952-Week Range$0.88▼$2.34Volume829,942 shsAverage Volume1.69 million shsMarket Capitalization$135.58 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company Overview Cardiol Therapeutics Inc. is a Canadian clinical-stage biotechnology company focused on developing therapies for inflammatory diseases of the heart and other cardiovascular conditions. The company is headquartered in Burlington, Ontario, and its shares trade on the Nasdaq Capital Market under the symbol CRDL. Cardiol’s lead product candidate, CardiolRx, is a pharmaceutical formulation of cannabidiol being investigated for its potential anti-inflammatory and cardioprotective properties. The company’s research has focused on conditions including acute myocarditis, an inflammation of the heart muscle, and recurrent pericarditis, an inflammatory disorder affecting the sac surrounding the heart. Cardiol conducts clinical development activities through research and trial programs in North America and other regions. The company is led by David Elsley, who serves as president and chief executive officer, with scientific and medical programs supported by researchers and clinicians specializing in cardiovascular disease and inflammation.AI Generated. May Contain Errors. Read More Cardiol Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreCRDL MarketRank™: 3.563913729615 of 5 starsCardiol Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 253rd out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingCardiol Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCardiol Therapeutics has a consensus price target of $10.00, representing about 777.2% upside from its current price of $1.14.Amount of Analyst CoverageCardiol Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Cardiol Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cardiol Therapeutics are expected to decrease in the coming year, from ($0.19) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiol Therapeutics is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiol Therapeutics is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiol Therapeutics has a P/B Ratio of 10.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cardiol Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.73% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 3.12, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cardiol Therapeutics has recently decreased by 7.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiol Therapeutics does not currently pay a dividend.Dividend GrowthCardiol Therapeutics does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment1.79 News SentimentCardiol Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cardiol Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for CRDL on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows4 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.25% of the stock of Cardiol Therapeutics is held by insiders.Percentage Held by Institutions12.49% of the stock of Cardiol Therapeutics is held by institutions.Read more about Cardiol Therapeutics' insider trading history. Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRDL Stock News HeadlinesCardiol Therapeutics (NASDAQ:CRDL) Stock Falls 5% - Here's Why2 hours ago | americanbankingnews.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiol Therapeutics (CRDL), Tyra Bioscience (TYRA) and Alibaba Health Information Technology (OtherALBHF)September 24, 2026 | theglobeandmail.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s EfficacySeptember 23, 2026 | prnewswire.comCardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in ProceedsSeptember 16, 2026 | prnewswire.comCardiol Therapeutics Details Long-Term Manufacturing and Development Agreements in September SEC FilingSeptember 11, 2026 | tipranks.comCardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities CommissionSeptember 10, 2026 | prnewswire.comCardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 9, 2026 | prnewswire.comSee More Headlines CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at $0.9538 on January 1st, 2026. Since then, CRDL stock has increased by 19.5% and is now trading at $1.14. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (NASDAQ:CRDL) posted its earnings results on Thursday, August, 13th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiol Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include Palantir Technologies (PLTR), NVIDIA (NVDA), Advanced Micro Devices (AMD), GeoVax Labs (GOVX), Palo Alto Networks (PANW), D-Wave Quantum (QBTS) and USA Rare Earth (USAR). Company Calendar Last Earnings8/13/2026Today10/15/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 13 days, CRDL's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CRDL CIK1702123 Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployees18Year Founded2017Price Target and Rating Average Price Target for Cardiol Therapeutics$10.00 High Price Target$11.00 Low Price Target$9.00 Potential Upside/Downside+777.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-180.44% Return on Assets-140.28% Debt Debt-to-Equity RatioN/A Current Ratio5.55 Quick Ratio5.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book10.36Miscellaneous Outstanding Shares118,930,000Free Float112,686,000Market Cap$135.58 million OptionableNot Optionable Beta0.88 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CRDL) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
